niacinamide has been researched along with Hematologic Malignancies in 11 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty-six patients with hematologic malignancies underwent transplantation at 11 sites." | 2.90 | Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide. ( Blackwell, B; Boelens, JJ; Cilloni, D; Frassoni, F; Freedman, LS; Hanna, R; Horwitz, ME; Hwang, WYK; Jagasia, M; Koh, LP; Kuball, J; Kurtzberg, J; Majhail, NS; Montesinos, P; Nierkens, S; Sanz, G; Stiff, PJ; Valcarcel, D; Wagner, JE; Wease, S, 2019) |
| "In a phase I trial, 11 adults with hematologic malignancies received myeloablative bone marrow conditioning followed by transplantation with NiCord and a second unmanipulated UCB unit." | 2.79 | Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. ( Aschengrau, D; Chao, NJ; Chute, JP; Cohen, EG; Friend, E; Gasparetto, C; Horwitz, ME; Kurtzberg, J; Landau, E; Long, GD; McDonald, C; Morris, A; Peled, A; Peled, T; Peleg, I; Rizzieri, DA; Shoham, H; Snyder, D; Stiff, P; Sullivan, KM; Waters-Pick, B; Wease, S; Yackoubov, D, 2014) |
| "Their hematological malignancies were well-controlled at the time of liver resection." | 1.46 | Liver resection for hepatocellular carcinoma in patients with hematological malignancies. ( Cheng, SB; Huang, CC; Jan, YG; Lin, HC; Lin, YL; P'eng, FK; Shen, CH; Teng, CJ; Wu, CC; Yang, YS, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Deeks, ED | 1 |
| Islam, P | 1 |
| Horwitz, ME | 3 |
| Romero, D | 1 |
| Lin, HC | 1 |
| Yang, YS | 1 |
| Teng, CJ | 1 |
| Shen, CH | 1 |
| Jan, YG | 1 |
| Cheng, SB | 1 |
| Wu, CC | 1 |
| Lin, YL | 1 |
| Huang, CC | 1 |
| P'eng, FK | 1 |
| Wease, S | 2 |
| Blackwell, B | 1 |
| Valcarcel, D | 1 |
| Frassoni, F | 1 |
| Boelens, JJ | 1 |
| Nierkens, S | 1 |
| Jagasia, M | 1 |
| Wagner, JE | 1 |
| Kuball, J | 1 |
| Koh, LP | 1 |
| Majhail, NS | 1 |
| Stiff, PJ | 1 |
| Hanna, R | 1 |
| Hwang, WYK | 1 |
| Kurtzberg, J | 2 |
| Cilloni, D | 1 |
| Freedman, LS | 1 |
| Montesinos, P | 1 |
| Sanz, G | 1 |
| Chao, NJ | 1 |
| Rizzieri, DA | 1 |
| Long, GD | 1 |
| Sullivan, KM | 1 |
| Gasparetto, C | 1 |
| Chute, JP | 1 |
| Morris, A | 1 |
| McDonald, C | 1 |
| Waters-Pick, B | 1 |
| Stiff, P | 1 |
| Peled, A | 1 |
| Snyder, D | 1 |
| Cohen, EG | 1 |
| Shoham, H | 1 |
| Landau, E | 1 |
| Friend, E | 1 |
| Peleg, I | 1 |
| Aschengrau, D | 1 |
| Yackoubov, D | 1 |
| Peled, T | 1 |
| Ravandi, F | 1 |
| Pigneux, A | 1 |
| DeAngelo, DJ | 1 |
| Raffoux, E | 1 |
| Delaunay, J | 1 |
| Thomas, X | 1 |
| Kadia, T | 1 |
| Kantarjian, H | 1 |
| Scheuenpflug, J | 1 |
| Zhao, C | 1 |
| Guo, W | 1 |
| Smith, BD | 1 |
| Walz, C | 1 |
| Erben, P | 1 |
| Ritter, M | 1 |
| Bloor, A | 1 |
| Metzgeroth, G | 1 |
| Telford, N | 1 |
| Haferlach, C | 1 |
| Haferlach, T | 1 |
| Gesk, S | 1 |
| Score, J | 1 |
| Hofmann, WK | 1 |
| Hochhaus, A | 1 |
| Cross, NC | 1 |
| Reiter, A | 1 |
| Podar, K | 1 |
| Anderson, KC | 1 |
| Zauli, G | 1 |
| Voltan, R | 1 |
| Tisato, V | 1 |
| Secchiero, P | 1 |
| Clemetson, KJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients With Hematological Malignancies[NCT01816230] | Phase 1/Phase 2 | 36 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Combination With a Second, Unmanipulated Cord Blood Unit in Patients With Hematological Malignancies[NCT01221857] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Assess the cumulative incidence of patients with NiCord®-derived neutrophil engraftment at 42 days following transplantation. (NCT01816230)
Timeframe: 42 days
| Intervention | percentage of patients (Number) |
|---|---|
| NiCord® | 94 |
Acute toxicity associated with the infusion of NiCord will be measured by adverse events within 24 hours post-infusion, defined as the acute toxicity period. Known adverse events associated with myeloablation and cord blood transplant were specifically monitored including fever, chills, allergic reaction/hypersensitivity, anaphylaxis, sinus bradycardia, sinus tachycardia, hypertension, hypotension, nausea, vomiting, diarrhea, dyspnea, hypoxia, hemoglobinuria, infection, flank pain and any other skin, CNS, cardiac, pulmonary or other toxicity manifestations. (NCT01221857)
Timeframe: 180 days post-transplant
| Intervention | Participants (Count of Participants) |
|---|---|
| NiCord | 0 |
Proportion of patients who had non-relapse mortality at 100 days. (NCT01221857)
Timeframe: 100 days
| Intervention | proportion of patients (Number) |
|---|---|
| Non-relapse Mortality | 0.09 |
"Acute GvHD was assessed from transplantation (day 0) until day 99 post-transplant or more frequently as clinically indicated. GvHD was classified according to the Glucksberg Classification (Glucksberg, Storb et al. 1974).~The overall grade of GvHD, however, was determined by an assessment of skin disease, liver disease and gastrointestinal manifestations." (NCT01221857)
Timeframe: 180 days
| Intervention | proportion of patients (Number) |
|---|---|
| Grade II-IV GvHD | 0.45 |
| Grade III-IV GvHD | 0 |
Neutrophil engraftment was defined as achieving an Absolute Neutrophil Count (ANC) of ≥500 mm3 for 3 consecutive measurements on different days by day 42 inclusive (the day of engraftment was defined as the first of these 3 days). The ANC recovery must be of donor origin documented by peripheral blood chimerism assays indicating less than or equal to 10% host cells in peripheral blood. (NCT01221857)
Timeframe: 42 days
| Intervention | proportion of patients (Number) |
|---|---|
| Neutrophil Engraftment | 0.91 |
4 reviews available for niacinamide and Hematologic Malignancies
| Article | Year |
|---|---|
Asciminib: First Approval.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhi | 2022 |
Small-molecule nicotinamide for ex vivo expansion of umbilical cord blood.
Topics: Allografts; Cell Division; Cells, Cultured; Clinical Trials as Topic; Cord Blood Stem Cell Transplan | 2019 |
Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Hematologic Neoplasms; Humans; I | 2011 |
State of the art of the therapeutic perspective of sorafenib against hematological malignancies.
Topics: Apoptosis; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Leuk | 2012 |
3 trials available for niacinamide and Hematologic Malignancies
| Article | Year |
|---|---|
Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide.
Topics: Adolescent; Adult; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Fetal Blood; | 2019 |
Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment.
Topics: Adult; Cord Blood Stem Cell Transplantation; Fetal Blood; Graft Survival; Hematologic Neoplasms; Hem | 2014 |
Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Hematologic Neoplasms; Humans; Middle Aged; Niacinam | 2015 |
4 other studies available for niacinamide and Hematologic Malignancies
| Article | Year |
|---|---|
Haematological cancer: Dual targeting to defeat resistance.
Topics: Hematologic Neoplasms; Humans; Niacinamide; Pyrazoles; Stress, Psychological | 2017 |
Liver resection for hepatocellular carcinoma in patients with hematological malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers; Carcinoma, Hepatocellul | 2017 |
Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3.
Topics: Adult; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Benzenesulfonates; DNA, Neoplasm; | 2011 |
American Society of Hematology--48th Annual Meeting and Exposition. Updates on therapies. 9-12 December 2006 Orlando, FL, USA.
Topics: Anemia, Sickle Cell; Antibiotics, Antineoplastic; Antigens, CD20; Benzamides; Benzenesulfonates; CD4 | 2007 |